<div id="readability-page-1"><p>Simplify Asset Management Inc. grew its stake in  Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 251.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor  owned 12,981 shares of the biopharmaceutical company's stock after acquiring an additional 9,284 shares during the period. Regeneron Pharmaceuticals accounts for  0.1% of Simplify Asset Management Inc.'s holdings, making the stock its 21st biggest holding. Simplify Asset Management Inc.'s holdings in Regeneron Pharmaceuticals were worth $7,299,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p><ul><li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li></ul><p>Several other hedge funds and other institutional investors also recently added to or reduced their stakes in REGN. PGGM Investments increased its holdings in  Regeneron Pharmaceuticals by 159.7% in the second quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company's stock valued at $44,308,000 after buying an additional 51,900 shares in the last quarter.  Founders Capital Management LLC grew its holdings in shares of  Regeneron Pharmaceuticals by 7.0% in the 2nd quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company's stock worth $4,344,000 after acquiring an additional 538 shares during the period.  Sepio Capital LP increased its stake in  Regeneron Pharmaceuticals by 33.1% in the 1st quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company's stock valued at $2,150,000 after purchasing an additional 842 shares in the last quarter.  Generate Investment Management Ltd acquired a new position in  Regeneron Pharmaceuticals during the second quarter worth $6,300,000.  Finally, Osaic Holdings Inc. boosted its position in  Regeneron Pharmaceuticals by 55.2% during the second quarter. Osaic Holdings Inc. now owns 17,068 shares of the biopharmaceutical company's stock worth $9,607,000 after purchasing an additional 6,073 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors. </p><h2>Analyst Ratings Changes</h2><p>Several research firms have recently issued reports on REGN. Royal Bank Of Canada lifted their price target on Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a &#34;sector perform&#34; rating in a research note on Wednesday, October 29th. HSBC started coverage on shares of Regeneron Pharmaceuticals in a research report on Monday, November 24th. They set a &#34;buy&#34; rating and a $255.00 target price for the company. Weiss Ratings  reissued a &#34;hold (c)&#34; rating on shares of Regeneron Pharmaceuticals in a research note on Monday, December 22nd. Canaccord Genuity Group increased their target price on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, December 4th. Finally, Wells Fargo &amp; Company upped their price objective on Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the company an &#34;equal weight&#34; rating in a research report on Wednesday, December 10th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eight have given a Hold rating and one  has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $779.45.</p><ul><li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li></ul><p><b>Read Our Latest Report on REGN</b></p><h2>Insider Buying and Selling</h2><p>In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 6,500 shares of the stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the completion of the sale, the director owned 2,352 shares of the company's stock, valued at $1,538,843.04. This trade represents a 73.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through the SEC website. Also, VP Jason Pitofsky sold 431 shares of the company's stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the transaction, the vice president owned 4,233 shares of the company's stock, valued at $2,757,503.19. This trade represents a 9.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 7.02% of the stock is owned by corporate insiders. </p><h2>Regeneron Pharmaceuticals Trading Down 0.6%</h2><ul><li>Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025</li></ul><p>REGN stock opened at $780.50 on Tuesday. The company has a market cap of $82.03 billion, a price-to-earnings ratio of 18.69, a PEG ratio of 2.26 and a beta of 0.37. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $792.77. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. The business has a fifty day simple moving average of $707.58 and a 200-day simple moving average of $612.72. </p><p>Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The business had revenue of $3.75 billion during the quarter, compared to analysts' expectations of $3.57 billion. During the same quarter in the previous year, the business earned $12.46 EPS. The company's revenue for the quarter was up .9% on a year-over-year basis.  On average, equities research analysts expect that  Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year. </p><h2>Regeneron Pharmaceuticals Dividend Announcement</h2><p>The business also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Shareholders of record on Thursday, November 20th were paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date was Thursday, November 20th. Regeneron Pharmaceuticals's payout ratio is currently 8.43%. </p><h2>Regeneron Pharmaceuticals Profile</h2> (Free Report)<p>Regeneron Pharmaceuticals, Inc <span>NASDAQ: REGN<span></span></span> is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.  </p><p>Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Regeneron Pharmaceuticals</li><li>Wall Street Stockpicker Names #1 Stock of 2026</li><li>ALERT: Drop these 5 stocks before January 2026!</li><li>How a Family Trust May Be Able To Help Preserve Your Wealth</li><li>Your “birthright claim” just got activated</li><li>Chilling warning from legendary investor</li></ul><p><strong>Want to see what other hedge funds are holding REGN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Regeneron Pharmaceuticals Right Now?</h2><p>Before you consider Regeneron Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.</p><p>While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

REGN

<p>Simplify Asset Management Inc. increased its stake in Regeneron Pharmaceuticals, Inc. by 251.1% in Q3, now owning 12,981 shares valued at $7.3 million. Other institutional investors also raised their stakes. Analyst ratings for REGN show a consensus of "Moderate Buy" with an average target price of $779.45. Recent insider sales include Director Christine A. Poon selling 6,500 shares. REGN stock opened at $780.50, with a market cap of $82.03 billion.</p>

Simplify Asset Management Inc. Raises Stake in Regeneron Pharmaceuticals, Inc. $REGN